Market Highlights:
Global Biomarkers Market: Information By Product (Consumables, Services, Software), By Type (Safety Biomarkers, Validation Biomarkers, Efficacy Biomarkers), By Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment) and By Disease Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, Others) – Forecast till 2027
Global Biomarkers Market is expected to have a market value of USD 64,265.19 Million by 2027. Increasing applications of biomarkers, R&D funding by pharmaceutical and biotechnology companies, rising prevalence of cancer, and other chronic diseases, and new initiatives for biomarker research. Additionally, the rapidly growing population worldwide and increasing product launches by major players are likely to enhance the growth of the global biomarkers market.
MRFR recognizes the following companies as the Key Players in the Global Biomarkers Market— Merck KGaA, Bio-Rad Laboratories, Abbott Laboratories, EKF Diagnostics, Enzo Biochem Inc., Meso Scale Diagnostics, LLC, Signosis, and PerkinElmer Inc. Qiagen N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1941
Segment Analysis
Global Biomarkers Market is Segmented Based on Product, Type, Application, and Disease Indication. The biomarkers market, based on product, has been segmented into consumables, services, and software.
The biomarkers market, based on type, has been segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers are further segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, and prognostic biomarkers. The global biomarkers market, by application, has been segmented into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, and others.
The global biomarkers market, by disease indication, has been segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others. The segment growth can be attributed to the ability of biomarkers to cover clinical needs from cancer to infectious disease applications.
Regional Analysis:
The global biomarkers market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas led the market and accounted for the largest share in 2019. The presence of prominent biopharmaceutical companies such as Merck Millipore, Bio-Rad Laboratories, Inc., Illumina, Inc., and Agilent Technologies in the US, facilitates early market initiation and prompt supply chain management. Players headquartered in other regions are also actively involved in the expansion of their facilities in the American countries to capture maximum share in the region.
The European biomarkers market has been further segmented into Western Europe and Eastern Europe. The Western Europe biomarkers market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe accounts for the second-largest share in the global biomarkers market. The rising number of conferences, seminars, and symposiums conducted by intergovernmental as well as not-for-profit organizations is increasing the level of awareness among the patients suffering from various types of cancers. For instance, European Cancer Patient Coalition (ECPC), an organization representing more than 447 organization in 46 EU and non-EU countries, in partnership with Cancer Drug Development Forum (CDDF), European Alliance for Personalized Medicine (EAPM), and International Quality Network for Pathology (IQN-Path), launched the first-ever Personalized Medicine Awareness Month in November 2018. In 2018, the Cancer Drug Development Forum (CDDF), in collaboration with ECPC, held a workshop on Biomarkers and Patients’ Access to Personalized Oncology Drugs in Europe. Such events by collaborative efforts are increasing the market size of biomarkers in Europe.
The biomarkers market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest CAGR over the forecast period from 2020 to 2027. This is owing to the growing patient population in this region. World Cancer Research Fund Data, 2018 analyzed that the age-standardized rate for all cancers for men and women together was highest in Australia, at 468.0 people per 100,000 population, which was followed by New Zealand at 438.1.
The Middle East & Africa biomarkers market is segmented into two major regions, namely the Middle East and Africa. The growth of the biomarkers market in the Middle East and Africa was considerably low in recent years. In the Middle East, the adoption rate of biomarkers was mainly in developing countries such as South Africa, the UAE, and Saudi Arabia.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/biomarker-market-1941
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
In a recent business intelligence study, FactMR presents the nitty-gritty of the global cancer biomarkers market considering 2015-2019 as the historic year and 2020–2025 as the stipulated time frame.
The business report highlights the drivers, restraints, opportunities and trends affecting cancer biomarkers market growth.
Further, all the market shares associated with the market as well as the segments are expressed in terms of value and volume.Cancer accounts for 8.3 million deaths annually.
Over the next two decades, 7 out of 10 patients are likely to suffer from this deadly disease.
The increasing prevalence of cancer has facilitated extensive research in the diagnosis and treatment of cancer.
Governments are increasingly funding clinical trials to assist companies in developing effective diagnostics and treatment for cancer.
